Recent large clinical trials of the effects of finerenone, a novel MR antagonist, on chronic kidney disease with type 2 diabetes have shown a significant reduction in cardiovascular and renal composite outcomes [33,34]. This evidence concerns the gene NR3C2 and chronic kidney disease.